



Medtronic plc (MDT)

Updated September 1st, 2026, by Aristofanis Papadatos

Key Metrics

Current Price:	\$94	5 Year CAGR Estimate:	8.2%	Market Cap:	\$121 B
Fair Value Price:	\$101	5 Year Growth Estimate:	4.0%	Ex-Dividend Date:	9/25/26
% Fair Value:	93%	5 Year Valuation Multiple Estimate:	1.5%	Dividend Payment Date:	10/16/26
Dividend Yield:	3.1%	5 Year Price Target	\$123	Years Of Dividend Growth:	48
Dividend Risk Score:	B	Sector:	Health Care	Rating:	Hold

Overview & Current Events

Medtronic is the largest manufacturer of biomedical devices and implantable technologies in the world. It serves physicians, hospitals, and patients in more than 150 countries and has about 95,000 employees. Medtronic has four operating segments: Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Medtronic has raised its dividend for 48 consecutive years. The \$121 billion market cap company generated \$36 billion in revenue in its last fiscal year.

Prospective Medtronic investors should note that the company has established tax residence in Ireland. Dividends are considered Irish source income and Irish dividend withholding tax may automatically be applied to Medtronic's dividend payments. Many investors will qualify for an exemption from this withholding tax.

In early September, Medtronic reported (9/1/26) results for the first quarter of fiscal 2027. Organic revenue grew 14% over the prior year's quarter thanks to strong growth in Cardiovascular and Diabetes. Earnings-per-share grew 15%, from \$1.26 to \$1.45, and exceeded the analysts' consensus by \$0.06. In addition, Medtronic raised its already positive guidance for fiscal 2027. It raised its guidance for growth of organic revenue from 6.75%-7.25% to 7.25%-7.75% and its guidance for adjusted earnings-per-share from \$5.90-\$6.00 to \$5.94-\$6.00. At the mid-point, this guidance implies 8% growth over the prior year. We have raised our forecast for earnings-per-share in fiscal 2027 from \$5.95 to \$5.97. Medtronic has beaten the analysts' estimates in 30 of the last 33 quarters.

Growth on a Per-Share Basis

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2032
EPS	\$4.60	\$4.77	\$5.22	\$4.59	\$4.44	\$5.55	\$5.29	\$5.20	\$5.49	\$5.53	\$5.97	\$7.26
DPS	\$1.72	\$1.84	\$2.00	\$2.16	\$2.32	\$2.52	\$2.72	\$2.77	\$2.81	\$2.85	\$2.88	\$3.34
Shares¹	1,369	1,354	1,341	1,352	1,354	1,345	1,333	1,325	1,288	1,288	1,288	1,200

Medtronic has grown its earnings-per-share by only 2.1% per year on average over the last nine years. This is a low growth rate but it has partly resulted from temporary headwinds, such as high cost inflation and supply chain issues.

The company has reduced its share count by only -1% per year on average over the last nine years. Moving forward, we anticipate that share repurchases will continue to aid bottom line growth to a small degree. In addition, Medtronic's pipeline in new treatments could lead to further market share gains.

The pandemic formed a headwind for Medtronic, especially with the deferral of elective procedures, but the company has proved resilient in the last five years, with record earnings in 2022. Medtronic benefits from long-term healthcare trends. Moreover, we expect business performance to improve as soon as supply chain issues ease and cost inflation moderates. Overall, we expect Medtronic to grow its earnings-per-share by 4.0% per year on average until 2032.

Valuation Analysis

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	Now	2032
Avg. P/E	17.7	17.3	17.3	22.6	24.4	21.2	16.3	15.9	15.7	16.8	15.7	17.0
Avg. Yld.	2.1%	2.2%	2.2%	2.1%	2.1%	2.1%	3.1%	3.3%	3.3%	3.1%	3.1%	2.7%

¹ In millions.

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Medtronic plc (MDT)

Updated September 1st, 2026, by Aristofanis Papadatos

Excluding the years 2020 and 2021, in which shares of Medtronic had an abnormally high price-to-earnings ratio due to low earnings, shares have traded hands at an average price-to-earnings ratio of 17.0 over the last decade. We believe that this is a fair valuation baseline, taking into consideration the quality of the company and average growth prospects. The stock is currently trading at an earnings multiple of 15.7. If it trades at fair valuation level in five years, it will enjoy a 1.5% annualized gain in its returns.

Medtronic has an exceptional dividend growth record, with 48 consecutive years of dividend growth. It has grown its dividend by 5.8% per year on average over the last decade and by 2.7% per year on average over the last 5 years, though the last three dividend raises were only 1.5%, 1.4% and 1.4%. The 3.1% dividend yield is not spectacular, but investors should be encouraged by the safety and growth over time.

Safety, Quality, Competitive Advantage, & Recession Resiliency

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027	2032
Payout	37%	39%	38%	47%	52%	45%	51%	53%	51%	52%	48%	46%


Medtronic’s most compelling competitive advantage is its intellectual leadership in a complicated industry within the healthcare sector. Medtronic also has a strong product pipeline that should drive its growth for the foreseeable future.

In the Great Recession, Medtronic proved resilient, with earnings-per-share of \$2.61, \$2.92, \$3.22, \$3.37, and \$3.46 during the 2007 through 2011 stretch. In addition, the dividend kept on rising every year as well. While the payout ratio has been climbing from 25% in 2009 to 48% today, there is still ample room for dividend growth combined with share repurchases. Moreover, Medtronic has a rock-solid balance sheet, which is essential during downturns.

Final Thoughts & Recommendation

From a quality, earnings and dividend growth standpoint, Medtronic is fairly attractive. The stock could offer an 8.2% total annual return over the next five years thanks to 4.0% growth of earnings-per-share, its 3.1% dividend and a 1.5% potential valuation tailwind. We maintain our hold rating.

Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



Medtronic plc (MDT)

Updated September 1st, 2026, by Aristofanis Papadatos

Income Statement Metrics

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Revenue	29,710	29,953	30,557	28,913	30,117	31,686	31,227	32,364	33,537	36,364
Gross Profit	20,416	20,886	21,402	19,489	19,634	21,541	20,508	21,148	20,050	21,918
Gross Margin	68.7%	69.7%	70.0%	67.4%	65.2%	68.0%	65.7%	65.3%	59.8%	60.3%
SG&A Exp.	10,018	10,238	10,418	10,109	10,148	10,292	10,415	10,736	10,849	11,784
D&A Exp.	2,917	2,644	2,659	2,663	2,702	2,707	2,697	2,647	2,861	2,958
Operating Profit	5,986	6,034	6,632	5,222	4,895	5,908	5,830	5,520	6,193	7,068
Operating Margin	20.1%	20.1%	21.7%	18.1%	16.3%	18.6%	18.7%	17.1%	18.5%	19.4%
Net Profit	4,028	3,104	4,631	4,789	3,606	5,039	3,758	3,676	4,692	4,837
Net Margin	13.6%	10.4%	15.2%	16.6%	12.0%	15.9%	12.0%	11.4%	14.0%	13.3%
Free Cash Flow	5,626	3,616	5,873	6,021	4,885	5,978	4,580	5,200	5,185	5,426
Income Tax	578	2,580	547	(751)	265	456	1,580	1,133	936	1,299

Balance Sheet Metrics

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Total Assets	99,857	91,393	89,694	90,689	93,083	90,981	90,948	89,981	91,680	93,028
Cash & Equivalents	4,967	3,669	4,393	4,140	3,593	3,714	1,543	1,284	8,965	9,220
Accounts Receivable	5,591	5,987	6,222	4,645	5,462	5,551	5,998	6,128	6,515	6,643
Inventories	3,338	3,579	3,753	4,229	4,313	4,616	5,293	5,217	5,476	5,951
Goodwill & Int. Ass.	61,922	61,266	60,519	58,904	59,701	56,097	56,269	54,211	53,404	52,733
Total Liabilities	49,527	40,571	39,482	39,817	41,481	38,259	39,283	39,561	43,424	42,956
Accounts Payable	1,555	1,628	1,953	1,996	2,106	2,276	2,662	2,410	2,449	2,644
Long-Term Debt	33,373	25,737	25,299	24,747	26,318	24,114	24,300	25,024	29,434	28,950
Shareholder's Equity	50,208	50,720	50,091	50,737	51,428	52,551	51,483	50,214	48,024	49,463
LTD/E Ratio	0.66	0.51	0.51	0.49	0.51	0.46	0.47	0.50	0.62	0.59

Profitability & Per Share Metrics

Year	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Return on Assets	4.0%	3.2%	5.1%	5.3%	3.9%	5.5%	4.1%	4.1%	5.2%	5.2%
Return on Equity	7.9%	6.2%	9.2%	9.5%	7.1%	9.7%	7.2%	7.2%	9.5%	9.8%
ROIC	4.8%	3.9%	6.1%	6.3%	4.7%	6.5%	4.9%	4.9%	6.1%	6.2%
Shares Out.	1,369	1,354	1,341	1,352	1,354	1,345	1,333	1,330	1,290	1,288
Revenue/Share	21.35	21.89	22.51	21.40	22.24	23.45	23.43	24.33	26.00	28.23
FCF/Share	4.04	2.64	4.33	4.46	3.61	4.42	3.44	3.91	4.02	4.21

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.